卡普拉西祖马布治疗免疫血栓性血栓性缺血性紫外线:现实世界多中心数据
Eleni Gavriilaki1, Emmanuel Nikolousis2, Eudoxia-Evaggelia Koravou1
1BMT Unit - Department of Hematology, G. Papanicolaou Hospital, Thessaloniki, Greece.
Frontiers in medicine
|October 30, 2023
概括
卡普拉西祖马布显著减少了免疫血栓性血栓性缺血性紫外线 (iTTP) 患者的复发,证明了其安全性和有效性. 观察到早期血小板正常化和低并发症率,用ADAMTS13水平来指导剂量以确保持续缓解.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫栓塞性血栓塞性紫外线 (iTTP) 是一种罕见的自身免疫性疾病,其特征是微血管病性血清性贫血,血栓塞性衰竭和器官损伤.
- 有限的现实世界数据存在于caplacizumab, iTTP的新型治疗剂.
- 了解caplacizumab在不同iTTP患者群体中的安全性和有效性至关重要.
研究的目的:
- 评估卡普拉西祖马布在患有免疫血栓性血栓塞性紫外线 (iTTP) 的患者中的安全性和有效性.
- 为了比较用caplacizumab治疗的患者与历史对照患者的结果.
- 评估卡普拉西祖马布对血小板数,ADAMTS13活性和复发率的影响.
主要方法:
- 这是一项多中心实验研究,涉及70名iTTP患者 (23名接受卡普拉西祖马布治疗,47名历史对照).
- 卡普拉西祖马布每天服用10毫克,剂量以ADAMTS13水平为指导.
- 治疗结果的比较,包括血交换要求,并发症率,死亡率和复发发病率.
主要成果:
- 卡普拉西祖马布治疗与早期血小板和ADAMTS13活动正常化有关.
- 在卡普拉西祖马布组 (9%) 与历史对照组 (62%) 相比,观察到明显较低的复发率 (p < 0.001).
- 在使用卡普拉西祖马布时,没有报告3级并发症或重大出血事件.
结论:
- 卡普拉西祖马布是一种安全有效的治疗iTTP,包括耐火病例.
- 以ADAMTS13水平为指导的剂量有助于降低复发率.
- 现实世界的数据支持caplacizumab在改善iTTP患者的治疗结果方面的作用.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


